Details of the Drug

General Information of Drug (ID: DM8TNX3)

Drug Name

Etizolam

Synonyms

Etizolam [INN:JAN]; Etizolamum [INN-Latin]; VMZUTJCNQWMAGF-UHFFFAOYSA-N; Y 7131; Y-7131; etizolam; 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine; 40054-69-1; 6-(o-Chlorophenyl)-8-ethyl-1-methyl-4H-s-triazolo(3,4-c)thieno(2,3-e)(1,4)-diazepine; 8-Ethyl-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine; A76XI0HL37; AHR 3219; BRN 0572740; C17H15ClN4S; Depas; NCGC00182031-01; UNII-A76XI0HL37

Indication

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Approved	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

342.8

Logarithm of the Partition Coefficient (xlogp)

2.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 2,488.6 mcgh/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2.83 h [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination: The amounts of etizolam excreted was 30% in urine was 70% in feces (in a rat study) [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 3.4 hours [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.16676 micromolar/kg/day [5]
Vd: The volume of distribution (Vd) of drug is 0.9 +/- 0.2 L/kg [4]

Chemical Identifiers

Formula: C17H15ClN4S
IUPAC Name: 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene
Canonical SMILES: CCC1=CC2=C(S1)N3C(=NN=C3CN=C2C4=CC=CC=C4Cl)C
InChI: VMZUTJCNQWMAGF-UHFFFAOYSA-N
InChIKey: 1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3

Cross-matching ID

PubChem CID: 3307
ChEBI ID: CHEBI:31583
CAS Number: 40054-69-1
DrugBank ID: DB09166
INTEDE ID: DR0665

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[7]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Gschwend MH, Guserle R, Erenmemisoglu A, Martin W, Tamur U, Kanzik I, Hincal AA: Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects. Arzneimittelforschung. 2007;57(6):315-9. doi: 10.1055/s-0031-1296625.
3	BDDCS applied to over 900 drugs
4	World Health Organization: Etizolam (INN) Pre-Review Report
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol. 2004 Aug;60(6):427-30.
7	Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007 Aug;32(4):333-41.
8	Etizolam (INN) Pre-Review Report.